Physician profile
Mark Rojewski
NPI 1154341071
$527.71
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2021: $77.19.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $130.78 | 2019-2021 | |
| Amgen INC. | $66.94 | 2019 | |
| Pfizer INC. | $65.02 | 2019 | |
| Lilly USA, LLC | $52.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.13 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $25.43 | 2019 | |
| Novo Nordisk INC | $25.26 | 2019 | |
| Ironshore Pharmaceuticals INC. | $24.70 | 2019 | |
| Merck Sharp & Dohme LLC | $23.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.11 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.29 | 2019 | |
| Sanofi Pasteur INC. | $11.23 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $10.87 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rojewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.